Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Allogene Therapeutics, Inc.    ALLO

ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/11/2019 11/12/2019 11/13/2019 11/14/2019 11/15/2019 Date
27.16(c) 26.67(c) 26.55(c) 27.15(c) 27.81(c) Last
237 801 294 839 135 261 350 814 191 254 Volume
-0.59% -1.80% -0.45% +2.26% +2.43% Change
More quotes
Financials (USD)
Sales 2019 -
EBIT 2019 -211 M
Net income 2019 -198 M
Finance 2019 330 M
Yield 2019 -
Sales 2020 -
EBIT 2020 -293 M
Net income 2020 -289 M
Finance 2020 477 M
Yield 2020 -
P/E ratio 2019 -14,2x
P/E ratio 2020 -10,1x
EV / Sales2019 -
EV / Sales2020 -
Capitalization 3 390 M
More Financials
Company
Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product... 
Sector
Biotechnology & Medical Research
Calendar
11/19 | 02:25pmPresentation
More about the company
Surperformance© ratings of Allogene Therapeutics, Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on ALLOGENE THERAPEUTICS, INC
11/11Allogene Therapeutics Announces Year-End 2019 Media Event and Investor Confer..
GL
11/06Allogene Therapeutics Announces Pre-Clinical Data Presentations Supporting Al..
GL
11/06ALLOGENE THERAPEUTICS : and Notch Therapeutics Announce Collaboration to Researc..
AQ
11/05ALLOGENE THERAPEUTICS, INC. : Entry into a Material Definitive Agreement (form 8..
AQ
11/05ALLOGENE THERAPEUTICS : Management's Discussion and Analysis of Financial Condit..
AQ
11/05ALLOGENE THERAPEUTICS : 3Q Earnings Snapshot
AQ
11/05ALLOGENE THERAPEUTICS, INC. : Results of Operations and Financial Condition (for..
AQ
11/05Allogene Therapeutics Reports Third Quarter 2019 Financial Results
GL
11/05Allogene Therapeutics and Notch Therapeutics Announce Collaboration to Resear..
GL
10/29Allogene Therapeutics to Report Third Quarter 2019 Financial Results on Novem..
GL
09/19Allogene Therapeutics Enters Research Collaboration Directed at Enhancing Fut..
GL
09/03Allogene Therapeutics Announces September 2019 Investor Conference Schedule
GL
08/07ALLOGENE THERAPEUTICS : Management's Discussion and Analysis of Financial Condit..
AQ
08/07ALLOGENE THERAPEUTICS : 2Q Earnings Snapshot
AQ
08/07ALLOGENE THERAPEUTICS, INC. : Results of Operations and Financial Condition (for..
AQ
More news
News in other languages on ALLOGENE THERAPEUTICS, INC

- No features available -

More news
Sector news : Biotechnology & Medical Research - NEC
11/14BEIGENE : FDA Gives Accelerated Approval to BeiGene's Brukinsa
DJ
11/14Walt Disney soars while Cisco disappoints
11/14THERMO FISHER SCIENTIFIC : Qiagen Shares Surge on Report Thermo Fisher Mulling D..
DJ
11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
DJ
11/07GILEAD SCIENCES : U.S. Sues HIV Drugmaker Gilead Alleging It Infringed on PrEP P..
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart ALLOGENE THERAPEUTICS, INC.
Duration : Period :
Allogene Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLOGENE THERAPEUTICS, INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 36,80  $
Last Close Price 27,81  $
Spread / Highest target 79,8%
Spread / Average Target 32,3%
Spread / Lowest Target -6,51%
EPS Revisions
Managers
NameTitle
David D. Chang President, Chief Executive Officer & Director
Arie S. Belldegrun Executive Chairman
Eric Schmidt Chief Financial Officer
Alison Moore Chief Technical Officer
Barbra Sasu Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALLOGENE THERAPEUTICS, INC.3.27%3 390
IQVIA HOLDINGS INC.26.11%28 427
LONZA GROUP33.49%25 529
CELLTRION, INC.--.--%20 414
SEATTLE GENETICS, INC.102.52%19 667
INCYTE CORPORATION36.34%18 675